AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation: Difference between revisions
m (Bot: Adding CME Category::Cardiology) |
|||
(3 intermediate revisions by one other user not shown) | |||
Line 2: | Line 2: | ||
{{Stroke}} | {{Stroke}} | ||
{{CMG}}; {{AE}} {{AO}} | {{CMG}}; {{AE}} {{AO}} | ||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)<ref name="pmid24503673">{{cite journal| author=Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL et al.| title=Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. | journal=Stroke | year= 2014 | volume= | issue= | pages= | pmid=24503673 | doi=10.1161/01.str.0000442009.06663.48 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24503673 }} </ref> == | |||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | |||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
|- | |- | ||
|colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Risk stratification tools in | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Risk stratification tools in [[atrial fibrillation]] that account for age and sex-specific differences in the incidence of [[stroke]] are recommended. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Considering the increased prevalence of AF with age and the higher risk of stroke in elderly women with AF, active screening (in particular of women >75 years of age) in primary care settings using pulse taking followed by an ECG as appropriate is recommended. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Considering the increased prevalence of AF with age and the higher risk of stroke in elderly women with AF, active screening (in particular of women >75 years of age) in primary care settings using [[pulse]] taking followed by an [[ECG]] as appropriate is recommended. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' New oral anticoagulants are a useful alternative to warfarin for the prevention of stroke and systemic thromboembolism in women with paroxysmal or permanent AF and prespecified risk factors (according to CHA2DS2-VASc) who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance 15 mL/min), lower weight (<50 kg), or advanced liver disease (impaired baseline clotting function). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' New oral anticoagulants are a useful alternative to [[warfarin]] for the prevention of [[stroke]] and systemic [[thromboembolism]] in women with paroxysmal or permanent AF and prespecified risk factors (according to CHA2DS2-VASc) who do not have a [[prosthetic heart valve]] or hemodynamically significant valve disease, severe [[renal failure]] ([[creatinine clearance]] 15 mL/min), lower weight (<50 kg), or advanced [[liver disease]] (impaired baseline clotting function). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Line 22: | Line 18: | ||
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | |colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki> Oral anticoagulation in women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1) is not recommended ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | |bgcolor="LightCoral"|<nowiki>"</nowiki> Oral [[anticoagulation]] in women aged ≤65 years with [[AF]] alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1) is not recommended. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Line 29: | Line 25: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki> Antiplatelet therapy is a reasonable therapeutic option for selected low-risk women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki> [[Antiplatelet drug|Antiplatelet therapy]] is a reasonable therapeutic option for selected low-risk women aged ≤65 years with [[AF]] alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Aging-associated diseases]] | [[Category:Aging-associated diseases]] | ||
Line 46: | Line 46: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 19:34, 14 March 2016
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
FDA on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
CDC on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation in the news | |
Blogs on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)[1]
Class I |
"1. Risk stratification tools in atrial fibrillation that account for age and sex-specific differences in the incidence of stroke are recommended. (Level of Evidence: A) " |
"2. Considering the increased prevalence of AF with age and the higher risk of stroke in elderly women with AF, active screening (in particular of women >75 years of age) in primary care settings using pulse taking followed by an ECG as appropriate is recommended. (Level of Evidence: B) " |
"3. New oral anticoagulants are a useful alternative to warfarin for the prevention of stroke and systemic thromboembolism in women with paroxysmal or permanent AF and prespecified risk factors (according to CHA2DS2-VASc) who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance 15 mL/min), lower weight (<50 kg), or advanced liver disease (impaired baseline clotting function). (Level of Evidence: A) " |
Class III (No Benefit) |
" Oral anticoagulation in women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1) is not recommended. (Level of Evidence: B) " |
Class IIa |
" Antiplatelet therapy is a reasonable therapeutic option for selected low-risk women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1). (Level of Evidence: B) " |
References
- ↑ Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL; et al. (2014). "Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. doi:10.1161/01.str.0000442009.06663.48. PMID 24503673.